Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05761886 · ClinicalTrials.gov registry record · NA

Rural Area Pharmacist Intervention for Diabetes

A NA study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
87
Enrollment target

NCT05761886: Completed NA study, sponsored by Wake Forest University Health Sciences.

NCT05761886 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05761886, a NA study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
87 participants
Enrollment target

Study Summary

The goal of the project is to inform the system leaders regarding the feasibility and utility of having an embedded telehealth-based clinical pharmacist at rural primary care practices for supportive disease management of patients with Type 2 diabetes (T2D) and whether continuing and expanding the program within the system is worthwhile.

Primary Outcome

Proportion of eligible patients enrolled

Interventions

  • OTHER telehealth-based clinical pharmacy intervention

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2023-05-16
Est. Completion 2025-03-26
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT05761886 record still lists

NCT05761886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 1 intervention - of which telehealth-based clinical pharmacy intervention is the first listed.

NCT05761886 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05761886 about?

NCT05761886 is a clinical study titled "Rural Area Pharmacist Intervention for Diabetes". The goal of the project is to inform the system leaders regarding the feasibility and utility of having an embedded telehealth-based clinical pharmacist at rural primary care practices for supportive disease management of patients with Type 2 diabetes (T2D) and whether continuing and expanding the p...

What is the current status of trial NCT05761886?

This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2023-05-16. Estimated completion is 2025-03-26.

What interventions are being tested in trial NCT05761886?

The interventions under investigation include: telehealth-based clinical pharmacy intervention (OTHER).

Who is sponsoring clinical trial NCT05761886?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05761886's enrollment target sits among peer trials

87 974th of 2000 higher than 1,025 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03292601 · 87 participants · NA

    Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)

  • NCT04291105 · 87 participants · Phase 2

    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

  • NCT04565795 · 87 participants · NA

    Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

  • NCT05607004 · 87 participants · Phase 2

    (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05761886, the US trial registry maintained by the National Library of Medicine. NCT05761886 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.